Nexalin Technology Inc. (NXL) - Total Liabilities
Based on the latest financial reports, Nexalin Technology Inc. (NXL) has total liabilities worth $808.36K USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Nexalin Technology Inc. - Total Liabilities Trend (2019–2025)
This chart illustrates how Nexalin Technology Inc.'s total liabilities have evolved over time, based on quarterly financial data. See working capital position of Nexalin Technology Inc. to evaluate short-term liquidity relative to the company's equity base.
Nexalin Technology Inc. Competitors by Total Liabilities
The table below lists competitors of Nexalin Technology Inc. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
UNITH LTD.
F:CM30
|
Germany | €1.61 Million |
|
Baijiayun Group Ltd
NASDAQ:RTC
|
USA | $47.11 Million |
|
Aspire BioPharma, Inc.
NASDAQ:ASBP
|
USA | $3.25 Million |
|
Rochester Resources Ltd
V:RCT
|
Canada | CA$51.18 Million |
|
Companhia Paranaense de Energia Pref ADR
NYSE:ELP
|
USA | $36.10 Billion |
|
Nordic LEVEL Group AB
ST:LEVEL
|
Sweden | Skr172.22 Million |
|
Tsodilo Resources Limited
V:TSD
|
Canada | CA$4.77 Million |
|
Rockhopper Exploration
LSE:RKH
|
UK | GBX114.05 Million |
Liability Composition Analysis (2019–2025)
This chart breaks down Nexalin Technology Inc.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Nexalin Technology Inc. stock valuation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.07 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.28 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.22 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Nexalin Technology Inc.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Nexalin Technology Inc. (2019–2025)
The table below shows the annual total liabilities of Nexalin Technology Inc. from 2019 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $887.33K | +62.31% |
| 2024-12-31 | $546.69K | +28.55% |
| 2023-12-31 | $425.28K | -78.23% |
| 2022-12-31 | $1.95 Million | -19.80% |
| 2021-12-31 | $2.44 Million | +42.54% |
| 2020-12-31 | $1.71 Million | +32.27% |
| 2019-12-31 | $1.29 Million | -- |
About Nexalin Technology Inc.
Nexalin Technology, Inc., a medical device company, designs and develops neurostimulation products for the treatment of mental health epidemic in the United States and China. The company offers Generation 1, an easy-to-administer medical device which utilizes bioelectronic medical technology to treat anxiety, insomnia, and depression without the need for drugs or psychotherapy; and Generation 2 a… Read more